Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI306 PCSK9 inhibitor in heterozygous familial hypercholesterolemia (China)
ChiCTR2000038782Phase 3Recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tafolecimab in familial hypercholesterolemia (FH) (4 arms), sponsored by Beijing An Zhen Hospital. Primary endpoint: Low-density lipoprotein cholesterol (LDL-C). Started Nov 2020; status: recruiting.
02
Drugs
tafolecimab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on ChiCTR2000038782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038782.